Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.75 below Dar Bioscience Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 373 other companies have achieved higher Quick Ratio than Dar Bioscience Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1744 to 2069.

Explain Quick Ratio?
How much Cash & cash equivalents DARE�s has?
What are DARE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DARE Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-11.96 %	-0.33 %	9.61 %	61.27 %	31.74 %
Y / Y Cash & cash equivalent Change	150.6 %	79.28 %	57.42 %	105.43 %	-69.33 %
Quick Ratio MRQ	0.75	0.88	1.04	1.09	0.26
DARE's Total Ranking	# 2069	# 1744	# 1659	# 1187	# 2397
Seq. Current Liabilities Change	-19.87 %	-10.84 %	11.64 %	10.38 %	-9.28 %
Seq. Cash & cash equivalent Change	-31.87 %	-25.06 %	7.09 %	358.3 %	-51.26 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 374
Healthcare Sector	# 684
Overall Market	# 2069

Quick Ratio Statistics
High	Average	Low
19.35	3.47	0.2
(Mar 31 2018)		(Mar 31 2024)

Financial Statements
Dar Bioscience Inc 's Current Liabilities	$ 17 Millions	Visit DARE's Balance sheet
Dar Bioscience Inc 's Cash & cash equivalent	$ 13 Millions	Visit DARE's Balance sheet
Source of DARE's Sales		Visit DARE's Sales by Geography

Cumulative Dar Bioscience Inc 's Quick Ratio

DARE's Quick Ratio for the trailling 12 Months

DARE Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	10.34 %	20.84 %	27.18 %	21.14 %	-8.21 %
Y / Y Cash & cash equivalent TTM Growth	86.6 %	32.91 %	34.43 %	29.66 %	-4.77 %
Quick Ratio TTM	0.95	0.84	0.74	0.65	0.56
Total Ranking TTM	# 4023	# 3129	# 2970	# 2522	# 2958
Seq. Current Liabilities TTM Growth	-2.7 %	-0.08 %	2.49 %	10.72 %	6.57 %
Seq. Cash & cash equivalent TTM Growth	10.63 %	12.97 %	16.65 %	28 %	-21.2 %

Quick ratio ranking by company, industry and sector >> Back to DARE Financial Strength Comparisons >> Go to Compare DARE Quick Ratio to its Competitors

News about Dar Bioscience Inc Quick Ratio

Dar Biosciences Smart Drug Delivery A Bright Spot Amid Industry Woes and Strategic Expansion,

Dar Bioscience Inc.: A New Frontier in Smart Drug Delivery and Contraception Amidst Industry Challenges In an era where innovation and strategic partnerships drive the healthcare sector, Dar Bioscience Inc. has emerged as a beacon of promise in the realm of reproductive health and beyond. Recently, the company secured an impressive $6 million installment of a non-dilutive grant, part of a substantial commitment of up to $49 million aimed at advancing its cutting-edge smart drug delivery device for contraception. This funding is not just a financial boost; it represents a validation of Dar Bioscience s commitment to transformative healthcare solutions in contraception, obesity, and metabolic disorders. A Financial MilestoneSince the inception of this funding initiative, which has now surpassed $37.8 million, Dar Bioscience has demonstrated significant financial vitality and growth potential. In the first quarter of 2025, the company reported a staggering year-on-year revenue increase of 173.35%. This performance starkly contrasts with the broader market, where most competitors in the healthcare sector have faced an alarming contraction in revenues, averaging a downturn of 41.81% during the same period.

On the trailing twelve months basis DARE Cash & cash equivalent more than doubled by 150.6 % in Q2 2026 year on year, while Current Liabilities faded to $17 millions, this led to increase in in Dar Bioscience Inc 's Quick Ratio to 0.95, Quick Ratio remained below DARE average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Dar Bioscience Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3129 to 4023.

Explain Quick Ratio?
How much Cash & cash equivalents DARE�s has?
What are DARE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 438
Healthcare Sector	# 900
Within the Market	# 4023

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.38	3.19	0.46
(Jun 30 2018)		(Mar 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Genelux Corporation	2.05	$ 29.870 Millions	$ 14.590 Millions
Opko Health Inc	2.01	$ 300.761 Millions	$ 149.367 Millions
Corcept Therapeutics Inc	2.00	$ 308.197 Millions	$ 153.802 Millions
Clene Inc	2.00	$ 9.700 Millions	$ 4.852 Millions
Blue Water Vaccines Inc	2.00	$ 5.942 Millions	$ 2.974 Millions
Vertex Pharmaceuticals Inc	1.99	$ 7,852.400 Millions	$ 3,937.900 Millions
Metavia Inc	1.99	$ 12.636 Millions	$ 6.346 Millions
Connect Biopharma Holdings Limited	1.93	$ 31.500 Millions	$ 16.301 Millions
Amarin Corp Plcuk	1.92	$ 314.850 Millions	$ 164.195 Millions
Mustang Bio inc	1.91	$ 15.150 Millions	$ 7.918 Millions
Therapeuticsmd Inc	1.84	$ 9.189 Millions	$ 5.003 Millions
Fortress Biotech Inc	1.81	$ 196.576 Millions	$ 108.829 Millions
Maravai Lifesciences Holdings Inc	1.77	$ 70.091 Millions	$ 39.519 Millions
Decoy Therapeutics Inc	1.77	$ 8.289 Millions	$ 4.680 Millions
Hyperion Defi inc	1.75	$ 9.637 Millions	$ 5.509 Millions
Verastem Inc	1.75	$ 136.400 Millions	$ 78.130 Millions
Urogen Pharma Ltd	1.74	$ 108.000 Millions	$ 61.915 Millions
Pyxis Oncology Inc	1.72	$ 47.141 Millions	$ 27.474 Millions
Ernexa Therapeutics Inc	1.71	$ 5.028 Millions	$ 2.932 Millions
Lantern Pharma Inc	1.70	$ 7.361 Millions	$ 4.323 Millions
Nuvectis Pharma inc	1.67	$ 22.160 Millions	$ 13.294 Millions
Quoin Pharmaceuticals Ltd	1.63	$ 10.800 Millions	$ 6.613 Millions
Mallinckrodt Plc	1.63	$ 1,075.800 Millions	$ 660.600 Millions
Macrogenics Inc	1.59	$ 173.305 Millions	$ 108.815 Millions
Fibrobiologics Inc	1.59	$ 3.515 Millions	$ 2.213 Millions
Sarepta Therapeutics Inc	1.57	$ 788.489 Millions	$ 502.908 Millions
Revium Rx.	1.55	$ 1.506 Millions	$ 0.971 Millions
Liquidia Corporation	1.50	$ 284.181 Millions	$ 189.298 Millions
Greenwich Lifesciences Inc	1.50	$ 8.876 Millions	$ 5.923 Millions
Arcutis Biotherapeutics Inc	1.49	$ 238.552 Millions	$ 160.340 Millions

Date modified: 2026-09-03T11:42:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.